28 June 2023
TruSpine Technologies plc
("TruSpine" or the "Company")
Loan repayment & Update
TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that, further to the announcement on 25 April 2023, the Company has repaid the £100,000 loan and accrued interest under the Loan Agreement with Annabel Schild. The Funding Loan was repaid from existing cash resources following receipt of a HMRC R&D tax credit of approximately £200,000 ("Tax Credit").
Update on Working Capital
The Company has limited working capital resources and continues to carefully manage its cash position.
Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 25 April 2023.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation, and the Directors of the Company are responsible for the release of this announcement.
Enquiries:
|
TruSpine Technologies Plc |
Tel: +44 (0)20 7118 0852 |
|
Laurence Strauss, Chief Executive Officer |
|
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser) |
Tel: +44 (0)20 7213 0880 |
|
Liam Murray / Ludovico Lazzaretti |
|
|
Oberon Capital (Joint Broker) |
|
|
Mike Seabrook / Chris Crawford |
|
|
Peterhouse Capital Limited (Joint Broker & Financial Adviser) |
|
|
Lucy Williams / Duncan Vasey |
|
|
Novus Communications (PR and IR) |
Tel: +44 (0)20 7448 9839 |
|
Alan Green / Jacqueline Briscoe |